ALPMY
Price
$9.54
Change
-$0.09 (-0.93%)
Updated
Jan 17 closing price
Capitalization
26.55B
17 days until earnings call
GRFS
Price
$7.28
Change
+$0.04 (+0.55%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
5.48B
40 days until earnings call
Ad is loading...

ALPMY vs GRFS

Header iconALPMY vs GRFS Comparison
Open Charts ALPMY vs GRFSBanner chart's image
Astellas Pharma
Price$9.54
Change-$0.09 (-0.93%)
Volume$161.86K
Capitalization26.55B
Grifols SA
Price$7.28
Change+$0.04 (+0.55%)
Volume$4.22K
Capitalization5.48B
ALPMY vs GRFS Comparison Chart
Loading...
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALPMY vs. GRFS commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALPMY is a StrongBuy and GRFS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ALPMY: $9.63 vs. GRFS: $7.24)
Brand notoriety: ALPMY and GRFS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ALPMY: 114% vs. GRFS: 101%
Market capitalization -- ALPMY: $26.55B vs. GRFS: $5.48B
ALPMY [@Pharmaceuticals: Major] is valued at $26.55B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.48B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALPMY’s FA Score shows that 1 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • ALPMY’s FA Score: 1 green, 4 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than ALPMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALPMY’s TA Score shows that 5 TA indicator(s) are bullish while GRFS’s TA Score has 3 bullish TA indicator(s).

  • ALPMY’s TA Score: 5 bullish, 4 bearish.
  • GRFS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ALPMY is a better buy in the short-term than GRFS.

Price Growth

ALPMY (@Pharmaceuticals: Major) experienced а +0.84% price change this week, while GRFS (@Pharmaceuticals: Major) price change was -4.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.33%. For the same industry, the average monthly price growth was -0.62%, and the average quarterly price growth was -7.03%.

Reported Earning Dates

ALPMY is expected to report earnings on Apr 24, 2025.

GRFS is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALPMY($26.6B) has a higher market cap than GRFS($5.48B). GRFS has higher P/E ratio than ALPMY: GRFS (68.68) vs ALPMY (37.59). ALPMY YTD gains are higher at: -0.311 vs. GRFS (-2.688). ALPMY has higher annual earnings (EBITDA): 247B vs. GRFS (640M). ALPMY has more cash in the bank: 397B vs. GRFS (544M). GRFS has less debt than ALPMY: GRFS (11.1B) vs ALPMY (30B). ALPMY has higher revenues than GRFS: ALPMY (1.52T) vs GRFS (6.54B).
ALPMYGRFSALPMY / GRFS
Capitalization26.6B5.48B486%
EBITDA247B640M38,594%
Gain YTD-0.311-2.68812%
P/E Ratio37.5968.6855%
Revenue1.52T6.54B23,244%
Total Cash397B544M72,978%
Total Debt30B11.1B270%
FUNDAMENTALS RATINGS
ALPMY vs GRFS: Fundamental Ratings
ALPMY
GRFS
OUTLOOK RATING
1..100
1565
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10087
PRICE GROWTH RATING
1..100
7559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALPMY's Valuation (7) in the null industry is in the same range as GRFS (8) in the Pharmaceuticals Major industry. This means that ALPMY’s stock grew similarly to GRFS’s over the last 12 months.

ALPMY's Profit vs Risk Rating (100) in the null industry is in the same range as GRFS (100) in the Pharmaceuticals Major industry. This means that ALPMY’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's SMR Rating (87) in the Pharmaceuticals Major industry is in the same range as ALPMY (100) in the null industry. This means that GRFS’s stock grew similarly to ALPMY’s over the last 12 months.

GRFS's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as ALPMY (75) in the null industry. This means that GRFS’s stock grew similarly to ALPMY’s over the last 12 months.

GRFS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ALPMY (100) in the null industry. This means that GRFS’s stock grew similarly to ALPMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALPMYGRFS
RSI
ODDS (%)
Bullish Trend 5 days ago
60%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
58%
Bullish Trend 5 days ago
69%
Momentum
ODDS (%)
Bearish Trend 5 days ago
64%
Bearish Trend 5 days ago
71%
MACD
ODDS (%)
Bullish Trend 5 days ago
53%
Bearish Trend 5 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
67%
Bearish Trend 5 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
68%
Bearish Trend 5 days ago
72%
Advances
ODDS (%)
Bullish Trend 5 days ago
64%
Bullish Trend 13 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
68%
Bearish Trend 5 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 5 days ago
76%
Aroon
ODDS (%)
Bearish Trend 5 days ago
72%
N/A
View a ticker or compare two or three
Ad is loading...
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

ALPMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-0.67%
ALPMF - ALPMY
37%
Loosely correlated
N/A
OPHLY - ALPMY
32%
Poorly correlated
-0.87%
OTSKY - ALPMY
21%
Poorly correlated
-0.34%
BAYRY - ALPMY
13%
Poorly correlated
+0.19%
ABBV - ALPMY
12%
Poorly correlated
+1.37%
More

GRFS and

Correlation & Price change

A.I.dvisor tells us that GRFS and GIFOF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and GIFOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-3.08%
GIFOF - GRFS
26%
Poorly correlated
N/A
BIIB - GRFS
20%
Poorly correlated
+0.16%
AMRN - GRFS
20%
Poorly correlated
-1.86%
ALPMY - GRFS
11%
Poorly correlated
-0.67%
SCLX - GRFS
9%
Poorly correlated
+5.25%
More